Table 1 Baseline characteristics of AF patients with cardiometabolic comorbidities and those without cardiometabolic comorbidities
From: Association between cardiometabolic comorbidity and mortality in patients with atrial fibrillation
Characteristics | All patients (N = 23,838) | AF + None Cardiometabolic Comorbidities (N = 5991) | AF + ≥ 1 Cardiometabolic Comorbidities (N = 17,847) | P |
|---|---|---|---|---|
Age, year (SD) | 63.9 ± 12.0 | 57.4 ± 12.6 | 66.1 ± 11.0 |  < 0.01 |
Female, n (%) | 9031 (37.9%) | 1870 (31.2%) | 7161 (40.1%) |  < 0.01 |
BMI, n (%) |  |  |  |  < 0.01 |
 Normal (< 24 kg/m2) | 7071 (33.1%) | 2043 (40.2%) | 5028 (30.8%) |  |
 Overweight (24–28 kg/m2) | 9734 (45.5%) | 2252 (44.3%) | 7482 (45.9%) |  |
 Obese (BMI ≥ 28 kg/m2) | 4587(21.4%) | 784 (15.4%) | 3803 (23.3%) |  |
Smoking, n (%) | 3659 (15.3%) | 991 (16.5%) | 2668 (15.0%) |  < 0.01 |
Persistent AF | 8454 (35.5%) | 1616 (27.0%) | 6838 (38.3%) |  < 0.01 |
Cardiometabolic Comorbidities, n (%) | ||||
 Hypertension | 14,517 (60.9%) | - | 14,517 (81.3%) |  |
 Heart failure | 4998 (21.0%) | - | 4998 (28.0%) |  |
 Vascular disease | 3589 (15.1%) | - | 3589 (20.1%) |  |
 Thromboembolism | 3393 (14.2%) | - | 3393 (18.0%) |  |
 Diabetes mellitus | 5477(23.0%) | - | 5477 (30.7%) |  |
Non-CVD, n (%) | ||||
 COPD | 203 (0.9%) | 16 (0.3%) | 187 (1.1%) |  < 0.01 |
 Renal dysfunction | 684 (2.9%) | 35 (0.6%) | 649 (3.6%) |  < 0.01 |
Treatment, n (%) | ||||
 Antiarrhythmic drugs | 8124 (34.1%) | 2417 (40.3%) | 5707 (32.0%) |  < 0.01 |
 Ventricular rate control | 10,090 (42.3%) | 1327 (22.2%) | 8763 (49.1%) |  < 0.01 |
 Anticoagulants | 14,648 (61.4%) | 3711 (61.9%) | 10,937 (61.3%) | 0.37 |
 ACEIs/ARBs | 7628 (32.0%) | 362 (6.0%) | 7266 (40.7%) |  < 0.01 |
 Statin | 8392 (35.2%) | 1000 (16.7%) | 7392 (41.4%) |  < 0.01 |
 History of RFCA, n (%) | 11,798 (49.5%) | 3955 (66.0%) | 7843 (44.0%) |  < 0.01 |